Stem cell therapy for COVID-19 lung damage trial pulled before it began
NCT ID NCT05491681
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study aimed to test whether infusing donor stem cells could help people recover from acute respiratory distress syndrome (ARDS) caused by COVID-19. The trial was withdrawn before enrolling any participants, so no results are available. The approach was based on earlier lab and animal studies suggesting stem cells might reduce lung inflammation and promote healing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- allogeneic bone marrow-derived mesenchymal stem cells (MSCs)
- What this could lead to
- If successful, this approach could point toward a treatment to help people recover from severe lung damage caused by COVID-19.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data exist. Early-phase stem cell studies often fail to show benefit or may have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why COVID-19 lungs fail: tiny blood vessel damage may be key
- Scientists probe why lung disease raises COVID-19 risk
- Experimental cell treatment shows promise for COVID-19 lung failure
- New anticoagulation strategy tested for dialysis circuits in ECMO patients
- New care pathway aims to save lives of ICU patients with breathing failure
- New ventilator strategy for obese ARDS patients under study